Loading…
Cryogenic OGS (BSE 544440)₹368.20−1.67%Industrial Products
In the Sep 2026 quarter (standalone), Cryogenic OGS reported sales of ₹30.08 Cr, up 43.0% from Sep 2025, and net profit of ₹6.99 Cr, up 16.7% year on year. For the year to Mar 2026, sales were ₹41.07 Cr and net profit ₹9.99 Cr.
Company filings, standalone accounts; latest reported quarter Sep 2026
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Sales | 13.03 | 19.05 | 21.04 | 20.03 | 30.08 |
| Expenses | 9.96 | 14.95 | 14.95 | 13.95 | 20.94 |
| Operating Profit | 3.99 | 3.99 | 5.98 | 5.98 | 8.97 |
| OPM % | 27.0% | 21.9% | 27.0% | 29.0% | 29.9% |
| Other Income | 0.00 | 0.00 | 1.99 | 0.99 | 0.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 3.99 | 5.01 | 6.99 | 5.99 | 8.99 |
| Tax % | 26.0% | 27.0% | 24.0% | 28.0% | 25.9% |
| Exceptional items | 0.00 | 0.00 | 0.93 | 0.00 | 0.00 |
| Net Profit | 3.01 | 2.99 | 5.99 | 3.99 | 6.99 |
| EPS (Rs) | 2.66 | 3.16 | 3.88 | 3.14 | 4.74 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 23.07 | 22.05 | 24.04 | 33.09 | 41.07 |
| Expenses | 18.95 | 15.94 | 17.94 | 24.92 | 28.89 |
| Operating Profit | 3.99 | 5.98 | 5.98 | 7.98 | 10.97 |
| OPM % | 18.9% | 26.0% | 25.9% | 23.9% | 28.0% |
| Other Income | 0.99 | 0.99 | 0.99 | 0.99 | 2.99 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 |
| Profit before tax | 3.99 | 4.99 | 6.99 | 8.01 | 12.99 |
| Tax % | 26.0% | 25.9% | 24.9% | 26.0% | 25.0% |
| Exceptional items | 0.08 | 0.15 | 0.19 | 0.02 | 1.55 |
| Net Profit | 2.99 | 3.99 | 4.99 | 5.99 | 9.99 |
| EPS (Rs) | 3.13 | 3.90 | 5.11 | 5.81 | 7.15 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.49 | 0.49 | 0.49 | 10.00 | 13.99 |
| Reserves | 13.00 | 17.00 | 21.98 | 17.99 | 39.98 |
| Borrowings | 1.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 7.04 | 6.03 | 5.02 | 5.02 | 12.06 |
| Total Liabilities | 22.02 | 24.02 | 27.99 | 34.01 | 67.03 |
| Fixed Assets | 8.01 | 7.01 | 7.01 | 7.01 | 16.02 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 |
| Investments | 0.99 | 0.99 | 1.99 | 1.99 | 1.99 |
| Other Assets | 14.02 | 15.02 | 18.99 | 25.01 | 47.01 |
| Inventories | 2.44 | 1.92 | 3.95 | 5.80 | 8.01 |
| Trade receivables | 2.63 | 5.13 | 5.33 | 6.60 | 4.79 |
| Cash & equivalents | 7.99 | 8.11 | 9.55 | 11.08 | 32.79 |
| Total Assets | 22.02 | 24.02 | 27.99 | 34.01 | 67.03 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 1.99 | 1.99 | 1.99 | 1.99 | 7.97 |
| Cash from investing activity | −0.99 | 0.00 | −0.99 | −0.99 | −20.98 |
| Cash from financing activity | −1.01 | −2.01 | 0.00 | 0.00 | 15.03 |
| Net cash flow | 1.01 | 0.00 | 0.00 | 1.01 | 3.01 |
| Capex | 1.83 | 0.40 | 0.00 | 0.28 | 2.97 |
| Free cash flow | 1.01 | 1.01 | 2.01 | 2.01 | 6.02 |
| CFO / OP % | 87.9% | 52.9% | 52.0% | 52.9% | 100.9% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 41 | 85 | 80 | 73 | 43 |
| Inventory days | 58 | 57 | 105 | 111 | 137 |
| Days payable | 160 | 161 | 115 | 56 | 43 |
| Cash conversion cycle | −61 | −20 | 70 | 127 | 137 |
| Working capital days | −50 | 16 | 63 | 96 | 92 |
| ROCE % | — | 33.0% | 34.0% | 32.0% | 30.0% |
For the Sep 2026 quarter, Cryogenic OGS reported sales of ₹30.08 Cr, up 43.0% year on year and net profit of ₹6.99 Cr, up 16.7% year on year. The operating margin was 29.9%.
Cryogenic OGS' sales for the year to Mar 2026 were ₹41.07 Cr.
Net profit for the year to Mar 2026 was ₹9.99 Cr. Earnings per share over the same trailing period were ₹7.15.
Cryogenic OGS reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹32.79 Cr.
Cash from operations was ₹7.97 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹6.02 Cr.